The calcitonin gene-related peptide (CGRP) monoclonal antibodies exhibited a significant and safe impact on monthly migraine days and associated medications usage. CGRP monoclonal antibody is from the family of neuropeptides release from the motor and sensory neurons. This meta-analysis was conducted to evaluate the role and safety of this neuropeptide in providing relief from episodic migraine.

The randomized controlled trials with associated data were searched from Web of Science, the Cochrane Library, MEDLINE, and EMBASE till April 2018. A total of 8 trials with 2292 patients were selected. As compared to placebo, CGRP monoclonal antibodies were observed to significantly reduce the monthly acute migraine-specific medicine consumption and monthly migraine days from the baseline. A ≥ 50% reduction from baseline in migraine days per month was noticed in the CGRP monoclonal antibodies group. However, no difference was seen among the groups related to adverse events.

As per the subgroup analysis results, the drugs that showed remarkable positive results were Fremanezumab, Erenumab and Galcanezumab. These findings exhibit a considerable impact of CGRP monoclonal antibodies role to lessen the migraine days and utilization of medication.